TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16166442

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg p.o. twice daily) plus docetaxel (75 mg/m(2) every 3 weeks)
Number of subjects: 56
Study: 12738091

Group type: EXPERIMENTAL
Intervention: Khat chewing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lettuce (control)
Number of subjects: 10
Study: 10512407

Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8940729

Group type: EXPERIMENTAL
Intervention: Hematopoietic growth factors (HGF) such as G-CSF and GM-CSF
Number of subjects: 16

Group type: COMPARATOR
Intervention: No HGF supplementation
Number of subjects: 16
Study: 1565246

Group type: EXPERIMENTAL
Intervention: EMG-assisted botulinum toxin (BOTOX) injections, N = 28
Number of subjects: 52

Group type: COMPARATOR
Intervention: Botulinum toxin (BOTOX) injections without EMG assistance, N = 24
Number of subjects: 52
Study: 3907967

Group type: EXPERIMENTAL
Intervention: Norethisterone oenanthate (NET OEN) 50 mg alone
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Norethisterone oenanthate (NET OEN) 50 mg with estradiol valerate (E2 Val.) 5 mg
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Norethisterone oenanthate (NET OEN) 50 mg with estradiol valerate (E2 Val.) 2.5 mg or estradiol cypionate (E2 Cyp.)
Number of subjects: 364
Study: 31483461

Group type: EXPERIMENTAL
Intervention: Short-term Treatment for Internet and Computer Game Addiction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list Control (WLC)
Number of subjects: 0
Study: 30152068

Group type: COMPARATOR
Intervention: Intravaginal progesterone‐releasing device (IVD) containing 0.78 g progesterone and saline (low P4 concentration)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Intravaginal progesterone‐releasing device (IVD) containing 1.56 g progesterone (high P4 concentration)
Number of subjects: 258
Study: 24810757

Group type: EXPERIMENTAL
Intervention: INVOS monitoring
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group without monitoring
Number of subjects: 200
Study: 24623511

Group type: EXPERIMENTAL
Intervention: Faster-paced sessions (intertrial interval of ∼250 ms)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Slower-paced sessions (intertrial interval of ∼1,600 ms)
Number of subjects: 7
Study: 22214276

Group type: EXPERIMENTAL
Intervention: BDP‐HFA (100 μg twice daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: BDP‐HFA
Number of subjects: 21
Study: 19581539

Group type: EXPERIMENTAL
Intervention: Temsirolimus 175 mg weekly for 3 weeks followed by 75 mg weekly
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Temsirolimus 175 mg weekly for 3 weeks followed by 25 mg weekly
Number of subjects: 162

Group type: COMPARATOR
Intervention: Investigator's choice therapy
Number of subjects: 162
Study: 17373594

Group type: EXPERIMENTAL
Intervention: Stretching program (SP) of the dominant quadriceps muscle
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Exhaustive eccentric exercise (ECC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Eccentric exercise followed by stretching program (ECC/STR)
Number of subjects: 30
Study: 15362749

Group type: EXPERIMENTAL
Intervention: Budesonide foam (2 mg/50 mL)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Betamethasone enema (5 mg/100 mL)
Number of subjects: 38
Study: 11458140

Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency articular facet denervation under fluoroscopic guidance
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham therapy (same procedure without effective denervation)
Number of subjects: 70
Study: 8420421

Group type: EXPERIMENTAL
Intervention: 40 mg ICI 204,219 orally
Number of subjects: 8

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 8
Study: 3535695

Group type: EXPERIMENTAL
Intervention: 3 ml of 0.9% saline containing 1.5 mg PGE2
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3 ml of 0.9% saline (placebo)
Number of subjects: 30
Study: 28965369

Group type: EXPERIMENTAL
Intervention: Fully Bilateral Balanced Occlusion (FBBO)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Buccalised Occlusion (BO)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Lingualised Occlusion (LO)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) for patient satisfaction
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) for prosthodontist satisfaction
Number of subjects: 86
Study: 27573605

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (glimepiride)
Number of subjects: 20
Study: 26508131

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 91

Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 91
Study: 24441085

Group type: EXPERIMENTAL
Intervention: Lullaby music
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 25

Group type: COMPARATOR
Intervention: No music (control)
Number of subjects: 25
Study: 21419317

Group type: EXPERIMENTAL
Intervention: Brown rice lees (LB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mixed-grain dietary product (MG)
Number of subjects: 30
Study: 18003765

Group type: EXPERIMENTAL
Intervention: Standard hemodialysis
Number of subjects: 4

Group type: COMPARATOR
Intervention: Biofeedback dialysis
Number of subjects: 4
Study: 16517534

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (80 mg/kg every 6 h, max 4.5 g/dose)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cefepime (50 mg/kg every 8 h, max 2 g/dose)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cefepime
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam and Cefepime
Number of subjects: 27
Study: 14680045

Group type: EXPERIMENTAL
Intervention: 2-mile run
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 11000319

Group type: EXPERIMENTAL
Intervention: Restorations placed using cotton rolls and aspiration isolation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Restorations placed using rubber dam isolation
Number of subjects: 100
Study: 9148225

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 86

Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 86
Study: 1601598

Group type: EXPERIMENTAL
Intervention: Home rehabilitation with planned physical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital rehabilitation
Number of subjects: 0
Study: 3547214

Group type: EXPERIMENTAL
Intervention: Oral salbutamol therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no betamimetic agents)
Number of subjects: 38
Study: 29766301

Group type: EXPERIMENTAL
Intervention: Sutures reinforced with non-absorbable mesh
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study: 27739087

Group type: EXPERIMENTAL
Intervention: Tonic infusion of hypertonic saline into the right anterior temporalis muscle
Number of subjects: 14

Group type: COMPARATOR
Intervention: Baseline condition
Number of subjects: 14

Group type: COMPARATOR
Intervention: Isotonic saline infusion
Number of subjects: 14
Study: 25721866

Group type: EXPERIMENTAL
Intervention: OM‐89S (6 mg daily for 10 days, placebo for 20 days)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (50 mg daily for 30 days)
Number of subjects: 451
Study: 23889885

Group type: EXPERIMENTAL
Intervention: Traumeel ointment (T-O)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Traumeel gel (T-G)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Diclofenac gel (D-G)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Traumeel ointment (T-O) and Traumeel gel (T-G)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 449
Study: 21078416

Group type: EXPERIMENTAL
Intervention: Participants in CSP 474
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participating sites
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-participating sites
Number of subjects: 0
Study: 20234828

Group type: EXPERIMENTAL
Intervention: Atomoxetine 1.2 mg/kg/day
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Atomoxetine 2.4 mg/kg/day
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 16728291

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 13 and n = 14)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (n = 12 and n = 14)
Number of subjects: 53
Study: 14966096

Group type: EXPERIMENTAL
Intervention: Regular completion of HRQL questionnaires and feedback to physicians
Number of subjects: 286

Group type: COMPARATOR
Intervention: Attention-control group (completion of questionnaires, but no feedback)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group (no HRQL measurement in clinic before encounters)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Feedback of HRQL data
Number of subjects: 286

Group type: COMPARATOR
Intervention: Instrument completion without feedback
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Explicit use of HRQL data in intervention group
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Overall patient management
Number of subjects: 286
Study: 11421997

Group type: EXPERIMENTAL
Intervention: Lamotrigine 100 mg single dose
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lamotrigine 100 mg single dose in severe cirrhosis (Child-Pugh grade B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lamotrigine 100 mg single dose in severe cirrhosis (Child-Pugh grade C)
Number of subjects: 36
Study: 9014993

Group type: EXPERIMENTAL
Intervention: Dofetilide 8 micrograms/kg
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Dofetilide 4 micrograms/kg
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Dofetilide (both doses)
Number of subjects: 91
Study: 8344127

Group type: EXPERIMENTAL
Intervention: Prednisone (1 mg.kg‐1.day‐1 for 10 days, then 0.3 mg.kg‐1.day‐1 for 50 days)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 3526590

Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31465849

Group type: EXPERIMENTAL
Intervention: Microvascular decompression (MVD) for hemifacial spasm (HFS)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Control group (100 patients without DFP)
Number of subjects: 636
Study: 29538662

Group type: EXPERIMENTAL
Intervention: Factual gain-framed messages
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Factual loss-framed messages
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Emotional gain-framed messages
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Emotional loss-framed messages
Number of subjects: 402
Study: 27567243

Group type: EXPERIMENTAL
Intervention: Intravenous glyburide
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 24448992

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 396

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 396
Study: 22113063

Group type: EXPERIMENTAL
Intervention: Elevated Aspartate transaminase (AST)
Number of subjects: 1783

Group type: EXPERIMENTAL
Intervention: Elevated Alanine transaminase (ALT)
Number of subjects: 1783
Study: 20045564

Group type: EXPERIMENTAL
Intervention: Heidelberg retina tomograph (HRT) Glaucoma Probability Score (GPS)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Visual field (VF) assessment
Number of subjects: 198
Study: 18938672

Group type: EXPERIMENTAL
Intervention: Active tryptophan depletion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15811647

Group type: EXPERIMENTAL
Intervention: Evidence-based lecture on the benefits of the polio vaccine
Number of subjects: 97

Group type: COMPARATOR
Intervention: Presentation from a visibly affected victim of polio
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Evidence-based lecture
Number of subjects: 97
Study: 12575962

Group type: COMPARATOR
Intervention: cTnT-negative patients with no ST
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: cTnT-positive patients with ST ≥2 mm
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: ST ≥2 mm on ECGs done after 6 h of symptom onset
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Elevated cTnT within 6 h of symptom
Number of subjects: 959
Study: 10587936

Group type: EXPERIMENTAL
Intervention: Enhanced Abbreviated treatment
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Standard treatment
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: 12-month course of treatment (including at least 6 months in a therapeutic community followed by outpatient treatment)
Number of subjects: 412
Study: 8916874

Group type: EXPERIMENTAL
Intervention: Bassini repair
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: McVay repair
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 315
Study: 1885899

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: H2-receptor antagonists
Number of subjects: 0
Study: 6859420

Group type: EXPERIMENTAL
Intervention: Appendectomy
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: No easy appendectomy
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control (no appendectomy)
Number of subjects: 184
Study: 31957654

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) for 6 months, including once weekly 90-minute in-facility exercise sessions and 4 days per week at-home exercise sessions.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) for 6 months.
Number of subjects: 15
Study: 30803386

Group type: EXPERIMENTAL
Intervention: Frequency Transposition (FT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Frequency Compression (FC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no frequency lowering)
Number of subjects: 10
Study: 28144724

Group type: EXPERIMENTAL
Intervention: Nasal naloxone 0.8 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nasal naloxone 1.6 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous naloxone 1.0 mg
Number of subjects: 12
Study: 26750736

Group type: EXPERIMENTAL
Intervention: CSI-CY (experimental group)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (current IEP)
Number of subjects: 61
Study: 25086209

Group type: EXPERIMENTAL
Intervention: Participants led to believe their food consumption was being recorded
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants' beliefs about their eating behaviour being monitored
Number of subjects: 0
Study: 22002479

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP/SMX) for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Metronidazole for 7 days (given if B hominis was still present)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spontaneous clearance (no treatment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP/SMX)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 40
Study: 19280185

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 17127224

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg administered as a single dose in a 1 hour infusion (250 ml) for perioperative prophylaxis
Number of subjects: 39
Study: 14985524

Group type: EXPERIMENTAL
Intervention: Individual counselling (7 consultations over 9 months)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Control group (received written information on lifestyle factors)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 299
Study: 11729380

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 724

Group type: COMPARATOR
Intervention: Mini-laparotomy cholecystectomy (MC)
Number of subjects: 724
Study: 9388809

Group type: EXPERIMENTAL
Intervention: Peer collaborative activity with higher metacognitive understanding children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment group membership (collaborative recall task)
Number of subjects: 0
Study: 7639364

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 3203179

Group type: EXPERIMENTAL
Intervention: Contingent token reinforcement intervention
Number of subjects: 1

Group type: COMPARATOR
Intervention: Goal-setting plus extinction procedure
Number of subjects: 1
Study: 31240723

Group type: EXPERIMENTAL
Intervention: TAU plus MOL
Number of subjects: 36

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 36
Study: 28830881

Group type: EXPERIMENTAL
Intervention: Allopurinol dose escalation (DE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (current dose for the first 12 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (DE and control)
Number of subjects: 0
Study: 26397083

Group type: EXPERIMENTAL
Intervention: Body weight‐supported treadmill training (BWSTT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (continued physical therapy)
Number of subjects: 24
Study: 23357640

Group type: EXPERIMENTAL
Intervention: Mud therapy (11 consecutive sessions of peloids applied to the knee)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Routine drug treatment (Control group)
Number of subjects: 147
Study: 22035459

Group type: EXPERIMENTAL
Intervention: Definitive chemoradiotherapy with cetuximab
Number of subjects: 420

Group type: COMPARATOR
Intervention: Definitive chemoradiotherapy without cetuximab (control)
Number of subjects: 420
Study: 19021289

Group type: EXPERIMENTAL
Intervention: Off-label use of vascular devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care with alternative devices
Number of subjects: 0
Study: 15191269

Group type: EXPERIMENTAL
Intervention: Perfectionism
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Cognitive bias
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Hopelessness
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Inpatient depression and suicidal ideation severity
Number of subjects: 121
Study: 11952546

Group type: EXPERIMENTAL
Intervention: Psoriasis Symptom Management Programme (PSMP)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard psoriasis treatment alone
Number of subjects: 93
Study: 9846680

Group type: EXPERIMENTAL
Intervention: IUI followed by timed intercourse
Number of subjects: 201

Group type: COMPARATOR
Intervention: IUI alone
Number of subjects: 201
Study: 8205404

Group type: EXPERIMENTAL
Intervention: Wax baths plus pulsed ultrasound (short-term application)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wax baths (short-term application)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pulsed ultrasound alone (short-term application)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise (short-term application)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wax baths plus pulsed ultrasound (long-term application)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wax baths (long-term application)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pulsed ultrasound alone (long-term application)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise (long-term application)
Number of subjects: 0
Study: 2572189

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg once daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Terfenadine 60 mg twice daily
Number of subjects: 41
Study: 1105489

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30658546

Group type: EXPERIMENTAL
Intervention: Stepped care
Number of subjects: 281

Group type: COMPARATOR
Intervention: Manualised treatment
Number of subjects: 281
Study: 29262824

Group type: EXPERIMENTAL
Intervention: Active manipulation of the sphenopalatine ganglion (SPG)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham manipulation of the sphenopalatine ganglion (SPG)
Number of subjects: 10
Study: 26334339

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control
Number of subjects: 89
Study: 23757615

Group type: EXPERIMENTAL
Intervention: SITA/MET FDC 50/500 mg b.i.d. (uptitrated to 50/1,000 mg b.i.d.)
Number of subjects: 1250

Group type: COMPARATOR
Intervention: MET 500 mg b.i.d. (uptitrated to 1,000 mg b.i.d.)
Number of subjects: 1250
Study: 21559034

Group type: EXPERIMENTAL
Intervention: WeighWell intervention (motivational interviewing techniques, energy deficit diet, increased physical activity, 12-week duration, 3 face-to-face consultations, 3 structured telephone calls)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Comparison group (no specific intervention details provided)
Number of subjects: 52
Study: 19628939

Group type: EXPERIMENTAL
Intervention: Music therapy (weekly sessions of individual, receptive music therapy using the validated 'U' technique)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reading sessions (control group)
Number of subjects: 30
Study: 17259554

Group type: EXPERIMENTAL
Intervention: Endocrine therapy combined with growth factor pathway inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective estrogen receptor modulator tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aromatase inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pure ER antagonists
Number of subjects: 0
Study: 15235928

Group type: EXPERIMENTAL
Intervention: Mizoribine (MZ) onlay therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 52